Skip to main content
SpringerLink
Log in

The association between impaired glucose tolerance and soluble CD40 ligand: a 15-year prospective cohort study

  • Original Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Background and aims

The aim of the present study was to assess soluble CD40 Ligand (sCD40L) levels in relation to impaired glucose tolerance (IGT) at population level.

Methods

This study is part of a prospective, population-based cohort study, carried out from 1990 to 2008 in northern Finland. Study members, born in 1935 and living in the City of Oulu, underwent oral glucose tolerance test (OGTT) and measurement of plasma sCD40L at three different time points during the 15-year follow-up. The total number of study members who underwent OGTT was 768 at the baseline, 557 at the first and 467 at the second follow-up. SCD40L levels in patients with IGT were compared with those in subjects with normal glucose tolerance or impaired fasting glucose (non-IGT).

Results

Geometric mean level of sCD40L was significantly higher in the IGT group compared with the non-IGT group at the baseline (0.42 vs. 0.27 ng/mL) and at the first follow-up (1.50 vs. 0.36 ng/mL) (repeated measures mixed models ANOVA, p < 0.05). At the second follow-up (age 72–73 years), however, the difference was not statistically significant (9.44 vs. 7.24 ng/mL). During the entire follow-up, the levels of sCD40L increased significantly both in IGT and non-IGT groups.

Conclusion

We found that plasma sCD40L level increases with age as well as there are elevated levels of plasma sCD40L in subjects with IGT compared with non-IGT. This may indicate an increased cardiovascular risk in older age and in subjects with IGT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ceriello A (2004) Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J 147:803–807

    Article  CAS  PubMed  Google Scholar 

  2. Grundy SM (2012) Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 59:635–643

    Article  CAS  PubMed  Google Scholar 

  3. DeFronzo RA, Abdul-Ghani M (2011) Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 108:3B–24B

    Article  CAS  PubMed  Google Scholar 

  4. Pamukcu B, Lip GY, Snezhitskiy V et al (2011) The CD40-CD40L system in cardiovascular disease. Ann Med 43:331–340

    Article  CAS  PubMed  Google Scholar 

  5. Coban E, Kucuktag S, Basyigit S (2007) Platelet activation in subjects with impaired glucose tolerance. Platelets 18:591–594

    Article  CAS  PubMed  Google Scholar 

  6. Antoniades C, Bakogiannis C, Tousoulis D et al (2009) The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54:669–677

    Article  CAS  PubMed  Google Scholar 

  7. Henn V, Slupsky JR, Grafe M et al (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594

    Article  CAS  PubMed  Google Scholar 

  8. Neubauer H, Setiadi P, Gunesdogan B et al (2010) Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in type 2 diabetes. Diabet Med 27:384–390

    Article  CAS  PubMed  Google Scholar 

  9. Varo N, Vicent D, Libby P et al (2003) Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107:2664–2669

    Article  CAS  PubMed  Google Scholar 

  10. Harding SA, Sommerfield AJ, Sarma J et al (2004) Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 176:321–325

    Article  CAS  PubMed  Google Scholar 

  11. Jinchuan Y, Zonggui W, Jinming C et al (2004) Upregulation of CD40–CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta 339:85–90

    Article  CAS  PubMed  Google Scholar 

  12. Lim HS, Blann AD, Lip GY (2004) Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 109:2524–2528

    Article  CAS  PubMed  Google Scholar 

  13. Lee WL, Lee WJ, Chen YT et al (2006) The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. Metabolism 55:1029–1034

    Article  CAS  PubMed  Google Scholar 

  14. Unek IT, Bayraktar F, Solmaz D et al (2010) Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism 59:305–313

    Article  CAS  PubMed  Google Scholar 

  15. Dallmeier D, Larson MG, Vasan RS et al (2012) Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham heart study. Diabetol Metab Syndr 4:28

    Article  PubMed  PubMed Central  Google Scholar 

  16. Desideri G, Ferri C (2003) Effects of obesity and weight loss on soluble CD40L levels. JAMA 289:1781–1782

    Article  PubMed  Google Scholar 

  17. Gokulakrishnan K, Deepa R, Mohan V et al (2006) Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome—the Chennai urban rural epidemiology study. Metabolism 55:237–242

    Article  CAS  PubMed  Google Scholar 

  18. Singh T, Newman AB (2011) Inflammatory markers in population studies of aging. Ageing Res Rev 10:319–329

    Article  CAS  PubMed  Google Scholar 

  19. Rajala U, Keinanen-Kiukaanniemi S, Uusimaki A et al (1995) Prevalence of diabetes mellitus and impaired glucose tolerance in a middle-aged finnish population. Scand J Prim Health Care 13:222–228

    Article  CAS  PubMed  Google Scholar 

  20. Rajala U, Qiao Q, Laakso M et al (2000) Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res Clin Pract 50:231–239

    Article  CAS  PubMed  Google Scholar 

  21. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553

    Article  CAS  PubMed  Google Scholar 

  22. World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organization, Geneva

    Google Scholar 

  23. American Diabetes Association (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34:S62–S69

    Article  CAS  PubMed Central  Google Scholar 

  24. Preciado-Puga MC, Malacera JM, Fajardo-Araujo ME et al (2014) Markers of the progression of complications in patients with type 2 diabetes: a 1-year longitudinal study. Exp Clin Endocrinol Diabetes 122:484–490

    Article  CAS  PubMed  Google Scholar 

  25. Lievens D, Zernecke A, Seijkens T et al (2010) Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 116:317–4327

    Article  CAS  Google Scholar 

  26. Schonbeck U, Varo N, Libby P et al (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268

    Article  CAS  PubMed  Google Scholar 

  27. Yan JC, Zhu J, Gao L et al (2004) The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes. Clin Chim Acta 343:155–159

    Article  CAS  PubMed  Google Scholar 

  28. Almdal T, Scharling H, Jensen JS et al (2004) The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 164:1422–1426

    Article  PubMed  Google Scholar 

  29. Yngen M, Ostenson CG, Hu H et al (2004) Enhanced P-selectin expression and increased soluble CD40 ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 47:537–540

    Article  CAS  PubMed  Google Scholar 

  30. de Lemos JA, Zirlik A, Schonbeck U et al (2005) Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas heart study. Arterioscler Thromb Vasc Biol 25:2192–2196

    Article  CAS  PubMed  Google Scholar 

  31. Dallmeier D, Larson MG, Wang N et al (2012) Addition of inflammatory biomarkers did not improve diabetes prediction in the community: the Framingham heart study. J Am Heart Assoc 1:e000869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Seijkens T, Kusters P, Engel D et al (2013) CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diabet Vasc Dis Res 10:115–122

    Article  CAS  Google Scholar 

  33. DECODE Study Group, The European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405

    Article  Google Scholar 

  34. Keaney JF Jr, Lipinska I, Larson MG et al (2008) Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham offspring study. Am Heart J 156:1003–1009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the whole study team for collaboration.

Author information

Authors and Affiliations

  1. Center for Life Course Epidemiology, University of Oulu, 5000, 90014, Oulu, Finland

    Hannamari Linna, Kadri Suija, Ulla Rajala, Jari Jokelainen, Sirkka Keinänen-Kiukaanniemi & Markku Timonen

  2. Oulu Health Center, Oulu, Finland

    Hannamari Linna & Sirkka Keinänen-Kiukaanniemi

  3. Department of Family Medicine, University of Tartu, Tartu, Estonia

    Kadri Suija

  4. Institute of Biomedicine and Biocenter of Oulu, University of Oulu, Oulu, Finland

    Karl-Heinz Herzig & Toni Karhu

  5. Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland

    Karl-Heinz Herzig & Toni Karhu

  6. Unit of General Practice, Oulu University Hospital, Oulu, Finland

    Jari Jokelainen & Sirkka Keinänen-Kiukaanniemi

Authors
  1. Hannamari Linna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kadri Suija
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulla Rajala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karl-Heinz Herzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toni Karhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jari Jokelainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sirkka Keinänen-Kiukaanniemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Markku Timonen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kadri Suija.

Ethics declarations

Conflict of interest

None of the authors have any conflict of interest in connection with the submitted article.

Ethical approval

The study protocol was approved by the Ethics Committee of the Faculty of Medicine, University of Oulu, Oulu, Finland.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Statement of human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments. No studies with animals were performed.

Funding

The work was done in the Center for Life Course Epidemiology, University of Oulu, Finland.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Linna, H., Suija, K., Rajala, U. et al. The association between impaired glucose tolerance and soluble CD40 ligand: a 15-year prospective cohort study. Aging Clin Exp Res 28, 1243–1249 (2016). https://doi.org/10.1007/s40520-015-0524-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40520-015-0524-z

Keywords

Search

Navigation